Skip to main content
21323 Suchergebnisse für:

Pseudomonas 

sortieren nach |
"Aktualität" sortiert die Ergebnisse nach Publikationsdatum. "Relevanz" berücksichtigt auch noch andere Faktoren wie zum Beispiel die Häufigkeit der Suchbegriffe im Text.
  1. Open Access 01.12.2024 | ReviewPaper

    Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta‑analysis

    Antimicrobial resistance (AMR) is a leading cause of death around the world, with the highest burdens in low-resource settings [ 1 ]. Antimicrobial resistance can be stated as the innate or acquired capacity of a microbe to impede the effectiveness …

  2. Open Access 01.12.2024 | Letter

    Pseudomonas fluorescens CRBSI outbreak: complying with the standardization of invasive procedures is a step ahead in the fight against antimicrobial resistance

    In the healthcare sector, the implementation of standardized procedures, such as those commonly employed in franchises to ensure consistent quality, remains underprioritized. Within this framework, we focus on the importance of standardized …

  3. 03.02.2024 | OriginalPaper

    Quercetin attenuates Pseudomonas aeruginosa-induced acute lung inflammation by inhibiting PI3K/AKT/NF-κB signaling pathway

    Pseudomonas aeruginosa is an opportunistic pathogen that commonly causes infections in immunocompromised individuals with significant morbidity and mortality. Quercetin is a natural flavonoid abundantly present in fruits and vegetables, exerting …

  4. Open Access 23.02.2024 | OriginalPaper

    Surgical Treatment of Persistent Pseudomonas aeruginosa Bacteraemia After n-Butyl-2-cyanoacrylate for Gastric Bleeding Varices

    n-Butyl-2-cyanoacrylate (NCBA) is an effective therapeutic option for bleeding gastric varices but can sometimes be associated with adverse effects. Persistent bacteraemia is an unusual complication with a high mortality rate. We report the case …

  5. Open Access 18.01.2024 | OriginalPaper

    Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022–2023

    Pseudomonas aeruginosa is a major cause of nosocomial infections, particularly in immune-compromised patients, and is associated with considerable morbidity and mortality [ 1 , 2 ]. The increasing global incidence of carbapenem-resistant P.

  6. Open Access 01.12.2024 | OriginalPaper

    Effectiveness of Umonium38 against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA)

    Effective disinfection is crucial for infection control as it helps to control potentially hazardous microorganisms, especially in laboratory environments. It is crucial to use validated decontamination protocols to effectively inactivate …

  7. Open Access 01.12.2024 | OriginalPaper

    Cholangitis with bacteremia due to Pseudomonas nitroreducens in a patient with pancreatic neuroendocrine tumors: a case report

    Pseudomonas nitroreducens is a gram-negative, motile, aerobic, rod-shaped, synchrotrophic bacterium inhabiting soils such as oil brines, paddy field drainage, and river sediments [ 1 – 3 ]. P. nitroreducens is well-known for its ability to …

  8. Open Access 29.12.2023 | OriginalPaper

    Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

    Carbapenem-resistant Gram-negative bacilli (CRGNB) are a major public health problem, recently described by WHO as a global crisis [ 1 ]. Since nosocomial and healthcare-associated infections caused by CRGNB organisms significantly increase …

  9. 10.01.2024 | OriginalPaper

    Population-based genomic surveillance of Pseudomonas aeruginosa causing bloodstream infections in a large Canadian health region

    Pseudomonas aeruginosa ranks among the top ten bacterial causes of bloodstream infections (BSIs) globally [ 1 , 2 ]. Overall, it is responsible for between 4 and 9% of culture-positive bacterial BSIs [ 1 – 3 ]. P. aeruginosa BSIs are linked with …

  10. Open Access 01.12.2024 | OriginalPaper

    Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study

    Pseudomonas aeruginosa ( P. aeruginosa ) is a ubiquitous microorganism that causes different types of infections, primarily in immunosuppressed patients, critical care patients, or those with comorbidities [ 1 ]. P. aeruginosa is also one of the …

  11. Open Access 01.12.2024 | OriginalPaper

    Fine particulate matter 2.5 induces susceptibility to Pseudomonas aeruginosa infection via expansion of PD-L1high neutrophils in mice

    Air pollution poses a serious global public health threat [ 1 ]. Particulate matter (PM) is among the most harmful air pollutants, including PM10, PM2.5, and ultrafine particles. PM10 particles are coarse, with an aerodynamic diameter of less than …

  12. Open Access 24.01.2024 | OriginalPaper

    Genomic epidemiology and molecular characteristics of blaNDM-1-positive carbapenem-resistant Pseudomonas aeruginosa belonging to international high-risk clone ST773 in the Gauteng region, South Africa

    Pseudomonas aeruginosa is an important opportunistic pathogen causing a wide range of healthcare-associated infections, including ventilator-associated pneumonia, catheter-associated urinary tract, surgical site, burn wound and bloodstream …

  13. 19.01.2024 | OriginalPaper

    Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species

    Cefiderocol is a recently approved cephalosporin exhibiting potent activity towards a broad spectrum of aerobic Gram-negative multi-drug-resistant (MDR) pathogens, including carbapenemase-producers. A recent meta-analysis showed that the …

  14. 28.02.2024 | Online First

    Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222)

    A case of sino-pulmonary infection with skull base osteomyelitis due to XDR-Pseudomonas aeruginosa in renal transplant recipient was successfully treated with investigational antibiotic, cefepime/zidebactam (WCK 5222). This case highlights …

  15. Open Access 01.12.2023 | OriginalPaper

    Acarbose reduces Pseudomonas aeruginosa respiratory tract infection in type 2 diabetic mice

    According to the International Diabetes Federation and the World Health Organization, as of 2021, approximately one in ten people worldwide have diabetes, with a total of 537 million diabetics [ 1 , 2 ]. Diabetes mellitus prevalence has been …

  16. Open Access 01.12.2023 | OriginalPaper

    Pseudomonas otitidis bacteremia in an immunocompromised patient with cellulitis: case report and literature review

    Pseudomonas otitidis is a species of Pseudomonas bacteria that was first registered as a new species in the United States in 2006 and was initially reported as a cause of ear infections [ 1 ]. In recent years, it has been reported to cause more …

  17. 02.12.2023 | OriginalPaper

    Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain

    The prevalence of carbapenem resistant Gram-negative bacteria is continuously increasing and represents a major global health problem. In Enterobacterales, carbapenem resistance is usually due to carbapenemase genes contained on transmissible …

  18. Open Access 01.12.2023 | OriginalPaper

    Antibiotic resistance profiles and associated factors of Pseudomonas Infections among patients admitted to large tertiary care hospital from a developing country

    Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that can live in various hosts, such as plants, animals, and people [ 1 ]. Even in environments with inadequate nutrient levels, it can persist in both community and hospital …

  19. Open Access 01.12.2023 | OriginalPaper

    Coronavirus disease 2019 (COVID-19)-associated brain abscesses caused by Pseudomonas aeruginosa and Aspergillus fumigatus: two case and a review of the literature

    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over 505 million people and had caused 6.2 million deaths worldwide by 23 April 2022 [ 1 ]. Bacterial and fungal …

  20. Open Access 01.12.2023 | OriginalPaper

    A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia

    Community-acquired pneumonia (CAP) is lung infection that started outside the hospital or within 48 h of hospital admission [ 1 ]. It is a prevalent infectious disease affecting the elderly, with more than 30–40% of cases hospitalized [ 2 ].

Suchergebnisse filtern:

e.Medpedia

Antimikrobielle Therapie bei Kindern und Jugendlichen

Pädiatrie
Um antibakterielle Therapie effektiv und rational zu gestalten, müssen das Spektrum der antimikrobiellen Aktivität eines Antibiotikums oder Chemotherapeutikums ebenso bekannt sein wie dessen pharmakokinetische Eigenschaften und unerwünschten Wirkungen. Die klinische Wirksamkeit eines von seinem antimikrobiellen Spektrum her geeignet scheinenden Präparats wird wesentlich von der Frage bestimmt, ob die in vivo erreichbare Serum- bzw. Gewebekonzentration die minimale Hemmkonzentration (MHK) des betreffenden Erregers am Infektionsort übersteigen wird. Die Auswahl des geeigneten Medikaments hängt daher neben dem antimikrobiellen Spektrum und pharmakokinetischen Eigenschaften entscheidend von klinischen Aspekten wie Infektionsort, Grundkrankheit, Alter, Vortherapie und möglicher Toxizität ab. Aufgrund der vielfältigen Einflüsse ist es nicht verwunderlich, dass nur in Ausnahmefällen ein einziges Antibiotikum als allein mögliche Wahl angesehen werden kann bzw. alle notwendigen Eigenschaften in idealer Weise auf sich vereint. Klinische Studien zum Nachweis der Wirksamkeit sollten Voraussetzung für den Einsatz eines Antibiotikums in der Kinder- und Jugendmedizin sein und sind relevanter als die antimikrobielle Aktivität alleine.

weitere e.Medpedia Einträge

Suchoperatoren:

„ ... ... “ Findet Dokumente mit genau dieser Wortgruppe in exakt dieser Schreibweise und Reihenfolge (z.B., "rheumatische Beschwerden").
AND / UND Findet Dokumente, in denen beide Begriffe zusammen vorkommen (z.B., alkohol UND demenz).
OR / ODER Findet Dokumente, in denen einer der beiden oder beide Begriffe vorkommen (z.B., hiv ODER aids).
Leerzeichen Findet Dokumente, in denen alle Begriffe vorkommen. Der Leerschritt wird als UND interpretiert (z.B., isolierte systolische hypertonie).
NOT / NICHT Findet Dokumente, in denen der Begriff nach NOT nicht vorkommt (z.B., sars NOT sars-cov-2).
COUNT(...)>n Findet Dokumente, in denen der gesuchte Begriff mehr als n mal vorkommt. n steht für eine beliebige Anzahl (z.B., COUNT(mammakarzinom)>8).
NEAR(..., ..., ) Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B., NEAR(covid, diabetes,20)).
* Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., thrombose*, *thrombose, *thrombose*).
? Findet Dokumente mit dem Suchbegriff in verschiedenen Schreibweisen, hier mit s oder z, also organisation und organization. Das ? steht für eine einzige Stelle (z.B., organi?ation).
& + - Sonderzeichen werden als UND interpretiert (z.B., Diagnose + Therapie).

Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen.

Fahren Sie mit der Maus über den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.